Electromed, Inc. Logo

Electromed, Inc.

ELMD

(2.0)
Stock Price

27,73 USD

9.86% ROA

15.32% ROE

36.16x PER

Market Cap.

181.965.003,00 USD

0.18% DER

0% Yield

11.34% NPM

Electromed, Inc. Stock Analysis

Electromed, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Electromed, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 Revenue Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

3 ROE

The stock's ROE falls within an average range (8.82%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (7%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 PBV

The stock's PBV ratio (2.37x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (123), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

Electromed, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Electromed, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Electromed, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Electromed, Inc. Revenue
Year Revenue Growth
2008 8.752.129
2009 12.998.627 32.67%
2010 14.303.848 9.12%
2011 19.003.507 24.73%
2012 19.524.489 2.67%
2013 15.104.422 -29.26%
2014 15.487.875 2.48%
2015 19.408.385 20.2%
2016 22.991.999 15.59%
2017 25.861.144 11.09%
2018 28.697.622 9.88%
2019 31.299.750 8.31%
2020 32.470.688 3.61%
2021 35.756.000 9.19%
2022 41.659.000 14.17%
2023 48.067.000 13.33%
2024 59.328.000 18.98%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Electromed, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2008 271.241
2009 357.871 24.21%
2010 600.986 40.45%
2011 1.033.693 41.86%
2012 920.769 -12.26%
2013 603.375 -52.6%
2014 466.063 -29.46%
2015 315.647 -47.65%
2016 380.392 17.02%
2017 596.876 36.27%
2018 251.443 -137.38%
2019 583.311 56.89%
2020 1.049.612 44.43%
2021 1.722.000 39.05%
2022 1.356.000 -26.99%
2023 916.000 -48.03%
2024 704.000 -30.11%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Electromed, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 12.617.973 100%
2013 11.673.068 -8.09%
2014 10.908.531 -7.01%
2015 11.974.384 8.9%
2016 14.386.563 16.77%
2017 16.402.214 12.29%
2018 19.596.053 16.3%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 31.692.000 100%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Electromed, Inc. EBITDA
Year EBITDA Growth
2008 627.434
2009 2.783.300 77.46%
2010 2.154.132 -29.21%
2011 2.319.379 7.12%
2012 1.147.365 -102.15%
2013 -1.220.857 193.98%
2014 -32.653 -3638.88%
2015 2.046.411 101.6%
2016 3.848.010 46.82%
2017 4.324.466 11.02%
2018 3.798.552 -13.85%
2019 3.743.738 -1.46%
2020 5.856.921 36.08%
2021 3.750.000 -56.18%
2022 3.600.000 -4.17%
2023 4.621.000 22.09%
2024 10.180.000 54.61%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Electromed, Inc. Gross Profit
Year Gross Profit Growth
2008 6.605.084
2009 9.658.586 31.61%
2010 10.596.339 8.85%
2011 13.777.506 23.09%
2012 14.145.079 2.6%
2013 10.449.050 -35.37%
2014 10.634.002 1.74%
2015 13.600.227 21.81%
2016 17.876.263 23.92%
2017 20.568.429 13.09%
2018 22.856.021 10.01%
2019 23.847.944 4.16%
2020 25.200.046 5.37%
2021 27.305.000 7.71%
2022 31.442.000 13.16%
2023 36.519.000 13.9%
2024 45.204.000 19.21%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Electromed, Inc. Net Profit
Year Net Profit Growth
2008 267.852
2009 1.332.906 79.9%
2010 916.338 -45.46%
2011 1.055.577 13.19%
2012 186.606 -465.67%
2013 -1.329.276 114.04%
2014 -1.288.594 -3.16%
2015 1.092.486 217.95%
2016 2.212.502 50.62%
2017 2.229.472 0.76%
2018 1.902.396 -17.19%
2019 1.969.218 3.39%
2020 4.161.000 52.67%
2021 2.362.000 -76.16%
2022 2.305.000 -2.47%
2023 3.166.000 27.2%
2024 7.312.000 56.7%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Electromed, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 1 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Electromed, Inc. Free Cashflow
Year Free Cashflow Growth
2008 -368.700
2009 -1.868.330 80.27%
2010 -176.184 -960.44%
2011 -2.540.629 93.07%
2012 -2.025.528 -25.43%
2013 823.285 346.03%
2014 1.126.862 26.94%
2015 2.156.707 47.75%
2016 1.589.382 -35.69%
2017 503.973 -215.37%
2018 1.870.423 73.06%
2019 1.201.486 -55.68%
2020 3.219.252 62.68%
2021 2.629.000 -22.45%
2022 -2.211.000 218.91%
2023 -401.000 -451.37%
2024 4.443.000 109.03%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Electromed, Inc. Operating Cashflow
Year Operating Cashflow Growth
2008 243.158
2009 -1.157.706 121%
2010 607.937 290.43%
2011 -1.415.104 142.96%
2012 -1.171.777 -20.77%
2013 1.876.657 162.44%
2014 2.062.661 9.02%
2015 2.781.214 25.84%
2016 2.166.903 -28.35%
2017 1.191.121 -81.92%
2018 2.442.200 51.23%
2019 2.589.874 5.7%
2020 4.196.448 38.28%
2021 3.077.000 -36.38%
2022 -686.000 548.54%
2023 1.315.000 152.17%
2024 4.489.000 70.71%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Electromed, Inc. Capital Expenditure
Year Capital Expenditure Growth
2008 611.858
2009 710.624 13.9%
2010 784.121 9.37%
2011 1.125.525 30.33%
2012 853.751 -31.83%
2013 1.053.372 18.95%
2014 935.799 -12.56%
2015 624.507 -49.85%
2016 577.521 -8.14%
2017 687.148 15.95%
2018 571.777 -20.18%
2019 1.388.388 58.82%
2020 977.196 -42.08%
2021 448.000 -118.12%
2022 1.525.000 70.62%
2023 1.716.000 11.13%
2024 46.000 -3630.43%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Electromed, Inc. Equity
Year Equity Growth
2008 4.041.019
2009 6.058.742 33.3%
2010 7.462.614 18.81%
2011 14.706.323 49.26%
2012 15.080.335 2.48%
2013 13.926.861 -8.28%
2014 12.720.495 -9.48%
2015 13.923.331 8.64%
2016 16.358.596 14.89%
2017 19.067.550 14.21%
2018 21.895.032 12.91%
2019 25.733.986 14.92%
2020 30.249.315 14.93%
2021 32.416.000 6.68%
2022 34.173.000 5.14%
2023 37.667.000 9.28%
2024 44.545.000 15.44%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Electromed, Inc. Assets
Year Assets Growth
2008 9.395.597
2009 11.461.098 18.02%
2010 14.143.237 18.96%
2011 20.868.932 32.23%
2012 20.921.024 0.25%
2013 17.555.827 -19.17%
2014 15.792.166 -11.17%
2015 17.405.054 9.27%
2016 20.587.261 15.46%
2017 23.060.649 10.73%
2018 26.638.204 13.43%
2019 29.354.188 9.25%
2020 33.244.563 11.7%
2021 37.109.000 10.41%
2022 41.364.000 10.29%
2023 45.806.000 9.7%
2024 52.885.000 13.39%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Electromed, Inc. Liabilities
Year Liabilities Growth
2008 5.354.578
2009 5.402.356 0.88%
2010 6.680.623 19.13%
2011 6.162.609 -8.41%
2012 5.840.689 -5.51%
2013 3.628.966 -60.95%
2014 3.071.671 -18.14%
2015 3.481.723 11.78%
2016 4.228.665 17.66%
2017 3.993.099 -5.9%
2018 4.743.172 15.81%
2019 3.620.202 -31.02%
2020 2.995.248 -20.86%
2021 4.693.000 36.18%
2022 7.191.000 34.74%
2023 8.139.000 11.65%
2024 8.340.000 2.41%

Electromed, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
6.36
Net Income per Share
0.6
Price to Earning Ratio
36.16x
Price To Sales Ratio
3.33x
POCF Ratio
20.54
PFCF Ratio
20.98
Price to Book Ratio
4.18
EV to Sales
3.03
EV Over EBITDA
22.36
EV to Operating CashFlow
18.31
EV to FreeCashFlow
19.14
Earnings Yield
0.03
FreeCashFlow Yield
0.05
Market Cap
0,18 Bil.
Enterprise Value
0,17 Bil.
Graham Number
8.35
Graham NetNet
3.21

Income Statement Metrics

Net Income per Share
0.6
Income Quality
1.76
ROE
0.12
Return On Assets
0.13
Return On Capital Employed
0.2
Net Income per EBT
0.72
EBT Per Ebit
1.07
Ebit per Revenue
0.15
Effective Tax Rate
0.28

Margins

Sales, General, & Administrative to Revenue
0.29
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.77
Operating Profit Margin
0.15
Pretax Profit Margin
0.16
Net Profit Margin
0.11

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
1.05
Free CashFlow per Share
1.01
Capex to Operating CashFlow
0.04
Capex to Revenue
0.01
Capex to Depreciation
0.47
Return on Invested Capital
0.11
Return on Tangible Assets
0.1
Days Sales Outstanding
160.45
Days Payables Outstanding
28.38
Days of Inventory on Hand
104.3
Receivables Turnover
2.27
Payables Turnover
12.86
Inventory Turnover
3.5
Capex per Share
0.05

Balance Sheet

Cash per Share
1,87
Book Value per Share
5,18
Tangible Book Value per Share
5.1
Shareholders Equity per Share
5.18
Interest Debt per Share
0.01
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-2.15
Current Ratio
5.75
Tangible Asset Value
0,04 Bil.
Net Current Asset Value
0,04 Bil.
Invested Capital
42405000
Working Capital
0,04 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
3945000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Electromed, Inc. Dividends
Year Dividends Growth

Electromed, Inc. Profile

About Electromed, Inc.

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.

CEO
Mr. James L. Cunniff
Employee
174
Address
500 Sixth Avenue NW
New Prague, 56071

Electromed, Inc. Executives & BODs

Electromed, Inc. Executives & BODs
# Name Age
1 Mr. Bradley M. Nagel
Chief Financial Officer, Treasurer & Secretary
70
2 Mr. James L. Cunniff
President, Chief Executive Officer & Director
70

Electromed, Inc. Competitors

NeuroPace, Inc. Logo
NeuroPace, Inc.

NPCE

(0.5)
Surmodics, Inc. Logo
Surmodics, Inc.

SRDX

(0.8)
Paragon 28, Inc. Logo
Paragon 28, Inc.

FNA

(1.5)
ProSomnus, Inc. Logo
ProSomnus, Inc.

OSA

(2.2)
LivaNova PLC Logo
LivaNova PLC

LIVN

(2.2)
Pulmonx Corporation Logo
Pulmonx Corporation

LUNG

(1.2)
Artivion, Inc. Logo
Artivion, Inc.

AORT

(0.5)
AxoGen, Inc. Logo
AxoGen, Inc.

AXGN

(1.2)
CONMED Corporation Logo
CONMED Corporation

CNMD

(1.5)